Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Public ClinicalTrials.gov record NCT02899195. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients with pleural mesothelioma that can not be surgically removed will receive durvalumab, in combination with standard chemotherapy of pemetrexed and cisplatin as first-line treatment. Durvalumab is a type of drug called a monoclonal antibody (a type of protein). Laboratory tests show that it works by allowing the immune system to detect your cancer and reactivates the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS).
Study identification
- NCT ID
- NCT02899195
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2017
- Primary completion
- Feb 15, 2020
- Completion
- Jun 28, 2023
- Last update posted
- Jul 4, 2023
2017 – 2023
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| Stanford Cancer Institute | Stanford | California | 94305 | — |
| University of Colorado, Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| University of Miami Hospital | Miami | Florida | 33136 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| NorthShore University HealthSystem | Evanston | Illinois | 60201 | — |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21287 | — |
| St. Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| Metro Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota | 55416 | — |
| Washington University in St Louis | St Louis | Missouri | 63110 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| New York University Laura and Isaac Perlmutter Cancer Center | New York | New York | 10016 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Hillman Cancer Center Research Pavilion | Pittsburgh | Pennsylvania | 15213 | — |
| UTSW Medical Center | Dallas | Texas | 75390 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| University of Washington Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Aurora Cancer Center | Wauwatosa | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02899195, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 4, 2023 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02899195 live on ClinicalTrials.gov.